Name:	O
___.	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
amoxicillin	O
/	O
amlodipine	O
Attending:	O
___.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
attach	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
===============	O
___	O
10:37AM	O
BLOOD	O
WBC-10.1*	O
RBC-3.58*	O
Hgb-11.4*	O
Hct-35.6*	O
MCV-99*	O
MCH-31.8	O
MCHC-32.0	O
RDW-16.2*	O
RDWSD-58.7*	O
Plt	O
___	O
___	O
10:37AM	O
BLOOD	O
Glucose-231*	O
UreaN-32*	O
Creat-1.7*	O
Na-139	O
K-5.3	O
Cl-107	O
HCO3-18*	O
AnGap-14	O
___	O
10:37AM	O
BLOOD	O
ALT-24	O
AST-38	O
AlkPhos-125	O
TotBili-1.5	O
___	O
10:37AM	O
BLOOD	O
Lipase-36	O
___	O
10:37AM	O
BLOOD	O
cTropnT-0.01	O
___	O
___	O
10:37AM	O
BLOOD	O
Albumin-4.1	O
___	O
06:01AM	O
BLOOD	O
Calcium-10.1	O
Phos-2.8	O
Mg-2.3	O
___	O
06:01AM	O
BLOOD	O
TSH-2.1	O
CXR	O
___	O
1.	O
Moderate	O
left	O
pleural	O
effusion,	O
with	O
associated	O
atelectasis.	O
No	O
other	O
focal	O
consolidations.	O
2.	O
Moderate	O
cardiomegaly.	O
No	O
evidence	O
of	O
pulmonary	O
edema.	O
LIVER/GALLBLADDER	O
US	O
___	O
1.	O
No	O
evidence	O
of	O
cholelithiasis	O
or	O
acute	O
cholecystitis.	O
No	O
intrahepatic	O
or	O
extrahepatic	O
biliary	O
dilatation.	O
2.	O
Focal,	O
non	O
dependent,	O
0.5	O
cm	O
calcification	O
adherent	O
to	O
the	O
gallbladder	O
wall,	O
likely	O
a	O
calcified	O
polyp.	O
3.	O
Mild	O
gallbladder	O
wall	O
thickening,	O
which	O
could	O
be	O
due	O
to	O
third	O
spacing.	O
4.	O
Trace	O
perihepatic	O
ascites.	O
RECOMMENDATION(S):	O
Consider	O
follow-up	O
abdominal	O
gallbladder	O
ultrasound	O
in	O
___	O
months	O
TTE	O
___	O
The	O
left	O
atrial	O
volume	O
index	O
is	O
normal.	O
There	O
is	O
no	O
evidence	O
for	O
an	O
atrial	O
septal	O
defect	O
by	O
2D/color	O
Doppler.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
a	O
normal	O
cavity	O
size.	O
There	O
is	O
mild	O
(non-obstructive)	O
focal	O
basal	O
septal	O
hypertrophy.	O
There	O
is	O
normal	O
regional	O
and	O
global	O
left	O
ventricular	O
systolic	O
function.	O
Quantitative	O
biplane	O
left	O
ventricular	O
ejection	O
fraction	O
is	O
65	O
%	O
(normal	O
54-73%).	O
There	O
is	O
no	O
resting	O
left	O
ventricular	O
outflow	O
tract	O
gradient.	O
Mildly	O
dilated	O
right	O
ventricular	O
cavity	O
with	O
moderate	O
global	O
free	O
wall	O
hypokinesis.	O
Tricuspid	O
annular	O
plane	O
systolic	O
excursion	O
(TAPSE)	O
is	O
depressed.	O
Intrinsic	O
right	O
ventricular	O
systolic	O
function	O
is	O
likely	O
lower	O
due	O
to	O
the	O
severity	O
of	O
tricuspid	O
regurgitation.	O
The	O
aortic	O
sinus	O
diameter	O
is	O
normal	O
for	O
gender	O
with	O
a	O
normal	O
ascending	O
aorta	O
diameter	O
for	O
gender.	O
The	O
aortic	O
arch	O
diameter	O
is	O
normal	O
with	O
a	O
normal	O
descending	O
aorta	O
diameter.	O
A	O
___	O
3	O
aortic	O
valve	O
bioprosthesis	O
is	O
present.	O
The	O
prosthesis	O
is	O
well	O
seated	O
with	O
HIGH	O
gradient.	O
There	O
is	O
a	O
paravalvular	O
jet	O
of	O
mild	O
to	O
moderate	O
[___]	O
aortic	O
regurgitation.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
with	O
no	O
mitral	O
valve	O
prolapse.	O
There	O
is	O
moderate	O
to	O
severe	O
[3+]	O
mitral	O
regurgitation.	O
The	O
pulmonic	O
valve	O
leaflets	O
are	O
normal.	O
The	O
tricuspid	O
valve	O
leaflets	O
appear	O
structurally	O
normal.	O
There	O
is	O
SEVERE	O
[4+]	O
tricuspid	O
regurgitation.	O
Due	O
to	O
acoustic	O
shadowing,	O
the	O
severity	O
of	O
tricuspid	O
regurgitation	O
may	O
be	O
UNDERestimated.	O
There	O
is	O
SEVERE	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
In	O
the	O
setting	O
of	O
at	O
least	O
moderate	O
to	O
severe	O
tricuspid	O
regurgitation,	O
the	O
pulmonary	O
artery	O
systolic	O
pressure	O
may	O
be	O
UNDERestimated.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
IMPRESSION:	O
severe	O
tricuspid	O
regurgitation;	O
moderate-to-severe	O
mitral	O
regurgitation;	O
severe	O
pulmonary	O
hypertension	O
Compared	O
with	O
the	O
prior	O
TTE	O
(images	O
reviewed)	O
of	O
___	O
,	O
the	O
mitral	O
and	O
tricuspid	O
regurgitation	O
are	O
both	O
WORSE.	O
DISCHARGE	O
LABS.	O
___	O
06:16AM	O
BLOOD	O
WBC-6.5	O
RBC-3.62*	O
Hgb-11.5*	O
Hct-35.9*	O
MCV-99*	O
MCH-31.8	O
MCHC-32.0	O
RDW-15.6*	O
RDWSD-56.8*	O
Plt	O
___	O
___	O
06:16AM	O
BLOOD	O
Glucose-156*	O
UreaN-46*	O
Creat-2.1*	O
Na-144	O
K-4.3	O
Cl-101	O
HCO3-30	O
AnGap-13	O
___	O
06:16AM	O
BLOOD	O
Calcium-10.8*	O
Phos-3.9	O
Mg-2.5	O
Brief	O
Hospital	O
Course:	O
TRANSITIONAL	O
ISSUES:	O
====================	O
Discharge	O
weight:	O
167.7	O
lbs	O
Discharge	O
creatinine:	O
2.1	O
Discharge	O
diuretic:	O
Torsemide	O
60mg	O
PO	O
daily	O
CARDIOLOGY:	O
[	O
]	O
Given	O
his	O
___	O
on	O
discharge,	O
he	O
was	O
given	O
a	O
diuresis	O
holiday	O
on	O
___	O
with	O
plan	O
to	O
resume	O
his	O
home	O
Torsemide	O
60mg	O
PO	O
daily	O
dose	O
on	O
___.	O
[	O
]	O
Please	O
obtain	O
BMP	O
at	O
___	O
NP	O
appt	O
on	O
___	O
to	O
follow	O
up	O
kidney	O
function.	O
[	O
]	O
If	O
blood	O
pressure	O
is	O
still	O
not	O
controlled	O
on	O
doxazosin,	O
consider	O
uptitrating	O
the	O
medication	O
further	O
or	O
adding	O
calcium	O
channel	O
blocker	O
as	O
additional	O
agent.	O
[	O
]	O
Consider	O
repeat	O
TTE	O
once	O
stabilized	O
as	O
an	O
outpatient	O
to	O
reassess	O
pulmonary	O
hypertension	O
found	O
on	O
TTE	O
while	O
inpatient	O
PCP:	O
[	O
]	O
Needs	O
repeat	O
RUQ	O
u/s	O
in	O
___	O
months	O
to	O
evaluate	O
a	O
gallbladder	O
polyp	O
identified	O
on	O
___	O
RUQ	O
u/s	O
incidentally.	O
ENDOCRINOLOGY:	O
[	O
]	O
___	O
benefit	O
from	O
an	O
MIBG	O
scan	O
as	O
an	O
outpatient	O
(has	O
endocrine	O
follow	O
up	O
on	O
___.	O
[	O
]	O
We	O
faxed	O
a	O
request	O
for	O
records	O
to	O
___	O
requesting	O
the	O
operative	O
report	O
and	O
genetic	O
testing	O
regarding	O
his	O
pheochromocytoma.	O
BRIEF	O
HOSPITAL	O
COURSE:	O
======================	O
___	O
Hx	O
HFpEF	O
___	O
HTN	O
i/s/o	O
pheochromocytoma	O
s/p	O
L	O
adrenalectomy	O
(___),	O
CAD	O
s/p	O
DES	O
to	O
___	O
LAD	O
(___),	O
severe	O
AS	O
s/p	O
___	O
3	O
TAVR	O
(___),	O
a-fib	O
on	O
apixaban,	O
SSS	O
s/p	O
dual	O
PPM	O
(___),	O
T2DM,	O
OSA	O
on	O
CPAP	O
who	O
presented	O
with	O
decompensated	O
HFpEF	O
in	O
setting	O
of	O
poorly	O
controlled	O
HTN.	O
Patient	O
had	O
BP	O
gradually	O
lowered	O
with	O
the	O
addition	O
of	O
doxazosin	O
and	O
was	O
managed	O
with	O
IV	O
diuretics	O
until	O
euvolemic,	O
after	O
which	O
he	O
was	O
transitioned	O
to	O
a	O
PO	O
regimen	O
and	O
discharged	O
home.	O
CORONARIES:	O
80%	O
pLAD	O
-->	O
Synergy	O
DES,	O
OMB	O
30%	O
PUMP:	O
Normal	O
biventricular	O
function	O
RHYTHM:	O
Atrial	O
fibrillation	O
ACUTE/ACTIVE	O
ISSUES:	O
====================	O
#	O
Decompensated	O
HFpEF	O
Patient	O
presented	O
with	O
acute	O
exacerbation	O
of	O
non-ischemic	O
HFpEF	O
in	O
setting	O
of	O
SBP	O
230s;	O
NYHA	O
I	O
(baseline),	O
ACC	O
C,	O
dry	O
weight	O
179lbs	O
(182lbs	O
on	O
admission);	O
initial	O
exam	O
was	O
warm	O
and	O
wet.	O
Suspect	O
exacerbation	O
was	O
triggered	O
by	O
hypertension	O
in	O
the	O
setting	O
of	O
recurrence	O
or	O
progression	O
of	O
prior	O
pheochromocytoma	O
vs	O
viral	O
URI	O
vs	O
diet/medication	O
noncompliance.	O
Patient	O
was	O
diuresed	O
with	O
IV	O
diuretics	O
(max	O
160mg	O
IV	O
Lasix	O
with	O
10mg/hr	O
gtt)	O
until	O
euvolemic,	O
and	O
then	O
transitioned	O
to	O
torsemide.	O
He	O
initially	O
received	O
80mg	O
Torsemide	O
on	O
___	O
but	O
given	O
___	O
he	O
was	O
given	O
a	O
diuresis	O
holiday	O
on	O
___	O
with	O
plan	O
to	O
resume	O
home	O
Torsemide	O
60mg	O
PO	O
daily	O
on	O
___.	O
-	O
PRELOAD:	O
Resume	O
home	O
torsemide	O
60mg	O
PO	O
daily	O
on	O
___	O
-	O
AFTERLOAD:	O
Continued	O
on	O
home	O
losartan	O
50mg	O
daily.	O
Pt	O
seen	O
by	O
endocrinology	O
(see	O
below),	O
who	O
recommended	O
doxazosin	O
-	O
uptitrated	O
to	O
6	O
mg	O
daily	O
with	O
no	O
evidence	O
of	O
orthostatic	O
hypotension.	O
-	O
NHBK:	O
Continued	O
on	O
home	O
labetalol	O
200mg	O
TID	O
#	O
HTN	O
#	O
Hx	O
pheochromocytoma	O
Presented	O
with	O
hypertension	O
without	O
evidence	O
of	O
end-organ	O
dysfunction	O
with	O
SBP	O
to	O
230s,	O
previously	O
reportedly	O
well-controlled	O
with	O
SBPs	O
in	O
130s	O
to	O
140s	O
at	O
home.	O
Initially	O
he	O
was	O
managed	O
with	O
a	O
nitroglycerin	O
drip	O
before	O
transitioning	O
to	O
a	O
PO	O
regimen.	O
Given	O
slow	O
elevation	O
in	O
normetanephrines,	O
endocrinology	O
was	O
consulted	O
for	O
?recurrence	O
of	O
prior	O
pheochromocytoma.	O
Per	O
endocrinology,	O
pre-test	O
probability	O
for	O
recurrence	O
of	O
pheo	O
is	O
low/medium.	O
Would	O
want	O
to	O
see	O
metanephrine	O
panel	O
>3x	O
ULN	O
to	O
pursue	O
further	O
inpatient	O
work-up,	O
and	O
results	O
returned	O
with	O
plasma	O
metanephrines	O
<3x	O
ULN,	O
indicating	O
appropriateness	O
for	O
outpatient	O
workup.	O
Has	O
outpatient	O
follow-up	O
for	O
consideration	O
of	O
nuclear	O
imaging	O
(patient	O
has	O
appointment	O
on	O
___.	O
-	O
Uptitrated	O
doxazosin,	O
BP	O
mgmt	O
as	O
above	O
-	O
Consider	O
outpatient	O
nuclear	O
imaging	O
#pHTN	O
PASP	O
55mmHg.	O
Likely	O
group	O
2	O
d/t	O
HFpEF.	O
No	O
hx	O
of	O
COPD	O
or	O
other	O
lung	O
disease.	O
Not	O
currently	O
on	O
O2,	O
breathing	O
comfortably.	O
-	O
CTM	O
as	O
outpatient	O
-	O
Consider	O
repeat	O
TTE	O
when	O
likely	O
euvolemic	O
as	O
an	O
outpatient	O
to	O
reassess	O
#	O
A-fib	O
#	O
SSS	O
s/p	O
dual	O
lead	O
PPM	O
(DDDR)	O
-	O
AC:	O
Continued	O
apixaban	O
2.5mg	O
BID	O
#	O
CAD	O
s/p	O
___	O
-	O
___:	O
Continued	O
clopidogrel	O
75mg	O
daily	O
-	O
Statin:	O
Continued	O
atorvastatin	O
40mg	O
daily	O
#CKD	O
Unclear	O
baseline	O
Cr,	O
was	O
down	O
to	O
1.1	O
one	O
year	O
prior,	O
most	O
recently	O
lowest	O
Cr	O
was	O
1.6.	O
Cr	O
2.1	O
on	O
discharge,	O
see	O
above	O
regarding	O
diuretic	O
plan.	O
CHRONIC/RESOLVED	O
ISSUES:	O
========================	O
#	O
T2DM	O
-	O
Maintained	O
on	O
ISS,	O
held	O
home	O
linagliptin,	O
but	O
resumed	O
on	O
discharge.	O
#	O
Foot	O
pain	O
-	O
Continued	O
home	O
gabapentin	O
#	O
Gout	O
-	O
Continued	O
home	O
allopurinol	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Losartan	O
Potassium	O
50	O
mg	O
PO	O
DAILY	O
2.	O
Gabapentin	O
600	O
mg	O
PO	O
QHS	O
3.	O
Allopurinol	O
___	O
mg	O
PO	O
DAILY	O
4.	O
Labetalol	O
200	O
mg	O
PO	O
TID	O
5.	O
linaGLIPtin	O
5	O
mg	O
oral	O
Daily	O
6.	O
Apixaban	O
2.5	O
mg	O
PO	O
BID	O
7.	O
Atorvastatin	O
40	O
mg	O
PO	O
QPM	O
8.	O
Torsemide	O
60	O
mg	O
PO	O
DAILY	O
9.	O
Clopidogrel	O
75	O
mg	O
PO	O
DAILY	O
10.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
11.	O
TraZODone	O
50	O
mg	O
PO	O
QHS	O
12.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Doxazosin	O
6	O
mg	O
PO	O
DAILY	O
2.	O
Allopurinol	O
___	O
mg	O
PO	O
DAILY	O
3.	O
Apixaban	O
2.5	O
mg	O
PO	O
BID	O
4.	O
Atorvastatin	O
40	O
mg	O
PO	O
QPM	O
5.	O
Clopidogrel	O
75	O
mg	O
PO	O
DAILY	O
6.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
DAILY	O
7.	O
Gabapentin	O
600	O
mg	O
PO	O
QHS	O
8.	O
Labetalol	O
200	O
mg	O
PO	O
TID	O
9.	O
linaGLIPtin	O
5	O
mg	O
oral	O
Daily	O
10.	O
Losartan	O
Potassium	O
50	O
mg	O
PO	O
DAILY	O
11.	O
Torsemide	O
60	O
mg	O
PO	O
DAILY	O
12.	O
TraZODone	O
50	O
mg	O
PO	O
QHS	O
13.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Decompensated	O
HFpEF	O
HTN,	O
history	O
of	O
pheochromocytoma	O
Atrial	O
fibrillation	O
Sick	O
sinus	O
syndrome	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Dear	O
Mr.	O
___,	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
you	O
were	O
short	O
of	O
breath	O
and	O
your	O
blood	O
pressures	O
were	O
very	O
high.	O
Please	O
see	O
below	O
for	O
more	O
information	O
on	O
your	O
hospitalization.	O
It	O
was	O
a	O
pleasure	O
participating	O
in	O
your	O
care!	O
What	O
happened	O
while	O
you	O
were	O
in	O
the	O
hospital?	O
-	O
We	O
gave	O
you	O
some	O
medications	O
to	O
bring	O
your	O
blood	O
pressure	O
down.	O
We	O
ordered	O
some	O
tests	O
to	O
see	O
if	O
your	O
elevated	O
pressure	O
could	O
be	O
related	O
to	O
your	O
prior	O
pheochromocytoma	O
-	O
the	O
results	O
were	O
inconclusive.	O
The	O
endocrinology	O
team	O
saw	O
you	O
while	O
you	O
were	O
here;	O
they	O
recommend	O
you	O
follow-up	O
with	O
your	O
endocrinologist	O
for	O
more	O
testing	O
as	O
an	O
outpatient.	O
-	O
We	O
believe	O
your	O
shortness	O
of	O
breath	O
was	O
related	O
to	O
your	O
heart	O
failure	O
causing	O
fluid	O
buildup	O
in	O
your	O
lungs.	O
When	O
your	O
blood	O
pressure	O
is	O
very	O
elevated	O
like	O
it	O
was,	O
that	O
can	O
cause	O
an	O
exacerbation	O
of	O
your	O
heart	O
failure.	O
-	O
We	O
gave	O
you	O
diuretic	O
medications	O
through	O
the	O
IV	O
to	O
help	O
remove	O
the	O
fluid	O
and	O
improve	O
your	O
heart	O
failure.	O
What	O
should	O
you	O
do	O
after	O
leaving	O
the	O
hospital?	O
-	O
Do	O
not	O
take	O
your	O
torsemide	O
today;	O
please	O
resume	O
your	O
regular	O
home	O
dose	O
of	O
torsemide	O
60mg	O
daily	O
on	O
___.	O
-	O
You	O
have	O
a	O
new	O
blood	O
pressure	O
medication	O
called	O
doxazosin.	O
You	O
should	O
take	O
6mg	O
(3	O
pills)	O
daily.	O
-	O
You	O
have	O
an	O
appointment	O
this	O
___	O
to	O
see	O
the	O
heart	O
failure	O
team.	O
They	O
will	O
check	O
your	O
weight	O
and	O
make	O
sure	O
your	O
kidney	O
function	O
is	O
ok.	O
-	O
Please	O
take	O
your	O
medications	O
as	O
listed	O
below	O
and	O
follow	O
up	O
at	O
the	O
listed	O
appointments.	O
-	O
Please	O
weigh	O
yourself	O
every	O
morning	O
and	O
call	O
your	O
doctor	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs.	O
We	O
wish	O
you	O
the	O
best!	O
-	O
Your	O
___	O
Healthcare	O
Team	O
Followup	O
Instructions:	O
___	O

